Tim is CEO and member of the Board of Directors of AgomAb, a Belgian based biotech company developing therapies that modulate regenerative pathways. The team raised around $100M financing from top US and EU investors.
Prior to AgomAb, Tim held the position of VP Corporate Development at AM-Pharma where he and the team executed a Phase IIb trial in patients with sepsis-associated acute kidney injury, secured an option-to-buy deal with Pfizer and raised significant private financing rounds.
Prior to that, Tim was a Senior Associate at Aescap Venture, a VC fund investing in European medical companies. Tim is a Henri Termeer Fellow and holds an executive MBA from IMD, where he was named Valedictorian. He earned a Science and Innovation Masters and a Drug Innovation Masters from Utrecht University.